1. Home
  2. ANVS vs ENTX Comparison

ANVS vs ENTX Comparison

Compare ANVS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANVS
  • ENTX
  • Stock Information
  • Founded
  • ANVS 2008
  • ENTX 2010
  • Country
  • ANVS United States
  • ENTX Israel
  • Employees
  • ANVS N/A
  • ENTX N/A
  • Industry
  • ANVS Biotechnology: Pharmaceutical Preparations
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ANVS Health Care
  • ENTX Health Care
  • Exchange
  • ANVS Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • ANVS 92.6M
  • ENTX 90.2M
  • IPO Year
  • ANVS 2020
  • ENTX 2018
  • Fundamental
  • Price
  • ANVS $2.73
  • ENTX $2.43
  • Analyst Decision
  • ANVS Strong Buy
  • ENTX Strong Buy
  • Analyst Count
  • ANVS 6
  • ENTX 1
  • Target Price
  • ANVS $31.40
  • ENTX $10.00
  • AVG Volume (30 Days)
  • ANVS 621.3K
  • ENTX 83.2K
  • Earning Date
  • ANVS 03-31-2025
  • ENTX 03-07-2025
  • Dividend Yield
  • ANVS N/A
  • ENTX N/A
  • EPS Growth
  • ANVS N/A
  • ENTX N/A
  • EPS
  • ANVS N/A
  • ENTX N/A
  • Revenue
  • ANVS N/A
  • ENTX $99,000.00
  • Revenue This Year
  • ANVS N/A
  • ENTX N/A
  • Revenue Next Year
  • ANVS N/A
  • ENTX N/A
  • P/E Ratio
  • ANVS N/A
  • ENTX N/A
  • Revenue Growth
  • ANVS N/A
  • ENTX 607.14
  • 52 Week Low
  • ANVS $2.44
  • ENTX $0.95
  • 52 Week High
  • ANVS $20.00
  • ENTX $3.35
  • Technical
  • Relative Strength Index (RSI)
  • ANVS 23.71
  • ENTX 54.06
  • Support Level
  • ANVS $2.44
  • ENTX $2.21
  • Resistance Level
  • ANVS $5.50
  • ENTX $2.62
  • Average True Range (ATR)
  • ANVS 0.31
  • ENTX 0.21
  • MACD
  • ANVS -0.11
  • ENTX -0.01
  • Stochastic Oscillator
  • ANVS 11.28
  • ENTX 69.35

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: